Proton Pump Inhibitors Market Size to Surpass US$ 5.64 Billion by 2031 - Growth Plus Reports

Newark, New Castle, USA, May 12, 2023 (GLOBE NEWSWIRE) -- According to a new Growth Plus Reports research, the global proton pump inhibitors market is expected to reach US$ 5.64 billion by 2031, with a revenue CAGR of 4.20%. The research looks at key tactics, trends and potential, competition, evolving industry dynamics, market size, statistics and projections, and key investment territories.

Key Takeaways:

• The increasing prevalence of GERD will drive market revenue growth.
• Bad eating habits, smoking, and obesity will drive demand for proton pump inhibitors.
• North America dominates the global proton pump inhibitors market. 

Request a Free Sample of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/proton-pump-inhibitors-market/8415

                                   Proton Pump Inhibitors Market Scope

Market Drivers
The rising prevalence of GERD and the increasing adoption of innovative medication delivery technologies will drive the revenue growth of the proton pump inhibitors market. Furthermore, factors such as aging, obesity, delayed stomach emptying, smoking habits, and consumption of alcohol, coffee, fatty, and fried foods are expected to boost the market revenue growth rate. The growing geriatric population and new product launches will support the market revenue growth.

Market Segmentation
Growth Plus Reports has analyzed the global proton pump inhibitors market from four perspectives: Drug Type, Distribution Channel, and Region.

Drug Type Segmentation: Based on the drug type, the global proton pump inhibitors market is segmented into omeprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole, and others. The esomeprazole segment dominates the market with the largest revenue share because it is the most commonly used drug for treating GERD, heartburn, and other stomach acid-related conditions.

Distribution Channel Segmentation: Based on the distribution channel, the global proton pump inhibitors market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacy segment dominates the market because of the high demand for PPIs in hospital settings and hospital pharmacies' advantages regarding purchasing power and resources.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/proton-pump-inhibitors-market/8415

Regional Growth Dynamics
Based on the region, the global proton pump inhibitors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global proton pump inhibitors market with the largest revenue share. A rise in the prevalence of GERD because of unhealthy lifestyles, an upsurge in PPI use, new product launches, rising awareness about the availability of PPIs as an effective treatment option, and growing healthcare expenditure are responsible for the significant revenue share in the global market.  

Asia Pacific is expected to register significant revenue growth in the coming years because of the increasing prevalence of gastroesophageal reflux disease (GERD) and peptic ulcers, growing awareness of PPIs, high healthcare spending, and the availability of generic PPIs.

Competitive Landscape

Some key players operating in the global proton pump inhibitors market are:

· Takeda Pharmaceuticals
· Cadila Pharmaceuticals
· Eli Lilly & Company
· Pfizer Inc.
· Teva Pharmaceuticals
· Janssen Global Services, LLC.
· AstraZeneca Plc
· Bayer AG
· Novo Nordisk A/S
· Cipla Limited

The proton pump inhibitors market is competitive with a number of global corporations. Leading players invest in technological advancements, research and development, and mergers and acquisitions to strengthen their market position.

Recent developments:

• Daewon Pharmaceutical introduced Escorten, one of Korea's first proton-pump inhibitor drugs, in April 2022. It is a 10mg esomeprazole magnesium trihydrate.
• TWI Pharmaceuticals USA announced the generic version of Dexilant in the United States in January 2022. It is a dexlansoprazole used to treat GERD (Gastroesophageal Reflux Disease) heartburn and heal erosive esophagitis. Dexlansoprazole delayed-release 30mg and 60mg capsules are available.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022)
   3. Regulatory Landscape
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL PROTON PUMP INHIBITORS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE
   1. Omeprazole
   2. Esomeprazol
   3. Pantoprazole
   4. Rabeprazole
   5. Dexlansoprazole
   6. Others
6. GLOBAL PROTON PUMP INHIBITORS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Others

PROTON PUMP INHIBITORS MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8415

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at - https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Eosinophilia Therapeutics Market by Drug Class (Corticosteroids, Immunosuppressant), Type (Blood Eosinophilia, Tissue Eosinophilia), Route of Administration (Oral, Intravenous) – Global Outlook & Forecast 2023-2031

Mortuary Bags Market by Material (PVC, Polyethylene), Size (Adult Bags, Child/Infant Bags), End User (Hospital, Morgue) – Global Outlook & Forecast 2023-2031

Asbestosis Treatment Market by Drug Class (Corticosteroids, Expectorants), Route of Administration (Oral, Inhalation) – Global Outlook & Forecast 2023-2031

Dental Consumables Market by Product (CAD/CAM Devices, Crowns & Bridges, Dental Biomaterials), End User (Hospitals, Dental Clinics) – Global Outlook & Forecast 2023-2031

Viral Vector Production Market by Type (Adenoviral Vectors, Adeno-associated Viral Vectors, Lentiviral Vectors), Disease (Cancer, Genetic Disorders, Infectious Diseases), Application (Gene Therapy, Vaccinology) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.